Discover how the groundbreaking AI-MARRVEL (AIM) system is revolutionizing the diagnosis of rare genetic disorders worldwide. Developed by an international team of experts, AIM significantly improves diagnosis accuracy by leveraging machine learning on real patient data. With its ability to identify causative variants and even discover new disease genes, AIM holds immense potential to transform clinical genomics and ensure more children receive life-changing genetic diagnoses.

Explore the groundbreaking collaboration between Cleveland Clinic and IBM, as researchers unveil an innovative AI-driven strategy for identifying immunotherapy targets. Discover the first peer-reviewed findings from their Discovery Accelerator partnership, revolutionizing cancer therapy research and pushing the boundaries of artificial intelligence in healthcare.